Be part of the knowledge.™

Oncology and Hematology

80

LikeLikedUnlike

Episodes 151-165 of 231

Patient Partners in NSCLC: Collaborating to Enhance Quality of Life and Outcomes With EGFRi-Associated Dermatologic Toxicities
CME/CE
Patient Partners in NSCLC: Collaborating to Enhance Quality of Life and Outcomes With EGFRi-Associated Dermatologic Toxicities
- Jonathan Leventhal, MD
  Peer
- Shahnaz Singh-Kandah, NP
  Peer
0.25 credits
MinuteCE®
Innovations in Oncology Learning Center: From Guidelines to Practice—Breast Cancer
- William J. Gradishar, MD
  Peer
- Erica L. Mayer, MD, MPH
  Peer
- Peter Schmid, FRCP, MD, PhD
  Peer
1.50 credits 10 episodes
MinuteCE®
Innovations in Oncology Learning Center From Guidelines to Practice: Gastrointestinal Cancers
- Sara Lonardi, MD
  Peer
- Aparna R. Parikh, MD
  Peer
- Alan Venook, MD
  Peer
1.25 credits 10 episodes
Immunotherapy for TNBC in the Perioperative Setting: Clinical Evidence and Considerations
MinuteCE®
Immunotherapy for TNBC in the Perioperative Setting: Clinical Evidence and Considerations
- Peter Schmid, FRCP, MD, PhD
  Peer
1.50 program credits
Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors
MinuteCE®
Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors
- Erica L. Mayer, MD, MPH
  Peer
1.50 program credits
Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC
MinuteCE®
Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC
- Peter Schmid, FRCP, MD, PhD
  Peer
1.50 program credits
advertisement
The Role of HER2-Directed Therapy for Second-Line Treatment of HER2+ Metastatic Breast Cancer
MinuteCE®
The Role of HER2-Directed Therapy for Second-Line Treatment of HER2+ Metastatic Breast Cancer
- Peter Schmid, FRCP, MD, PhD
  Peer
1.50 program credits
Guideline Recommendations for the Definition and Treatment of HER2-Low Breast Cancer
MinuteCE®
Guideline Recommendations for the Definition and Treatment of HER2-Low Breast Cancer
- Erica L. Mayer, MD, MPH
  Peer
1.50 program credits
Emerging Treatment Approaches for EBC
MinuteCE®
Emerging Treatment Approaches for EBC
- William J. Gradishar, MD
  Peer
1.50 program credits
The Evolving Treatment Landscape for MBC: Emerging Therapies
MinuteCE®
The Evolving Treatment Landscape for MBC: Emerging Therapies
- William J. Gradishar, MD
  Peer
1.50 program credits
Expert Viewpoint: Optimizing Breast Cancer Treatment
MinuteCE®
Expert Viewpoint: Optimizing Breast Cancer Treatment
- William J. Gradishar, MD
  Peer
- Erica L. Mayer, MD, MPH
  Peer
- Peter Schmid, FRCP, MD, PhD
  Peer
1.50 program credits
Management of HR+, HER2- High-Risk EBC
MinuteCE®
Management of HR+, HER2- High-Risk EBC
- Erica L. Mayer, MD, MPH
  Peer
1.50 program credits
advertisement
Management of HER2-Low MBC Following First-Line Disease Progression
MinuteCE®
Management of HER2-Low MBC Following First-Line Disease Progression
- Peter Schmid, FRCP, MD, PhD
  Peer
1.50 program credits
Biomarker-Directed Approaches for Frontline Treatment of Advanced Gastric/GEJ Cancers: The Evidence
MinuteCE®
Biomarker-Directed Approaches for Frontline Treatment of Advanced Gastric/GEJ Cancers: The Evidence
- Sara Lonardi, MD
  Peer
1.25 program credits
The Role of Biomarker-Driven Therapies in the Second-Line Treatment of Advanced Gastric/GEJ Cancers: What Do the Data Say?
MinuteCE®
The Role of Biomarker-Driven Therapies in the Second-Line Treatment of Advanced Gastric/GEJ Cancers: What Do the Data Say?
- Sara Lonardi, MD
  Peer
1.25 program credits

Program Chapters

Segment Chapters

Playlist:

Recommended